Download PDF
Physikalische Medizin, Rehabilitationsmedizin, Kurortmedizin
DOI: 10.1055/a-2116-8022
Original Article

Efficacy and Safety of Trigeminal Nerve Stimulation for Migraine: A Meta-Analysis of Randomized Controlled Studies

Wirksamkeit und Sicherheit der trigeminalen Nervenstimulation bei Migräne: eine Metaanalyse randomisierter kontrollierter Studien
Chunyan Deng
1   Department of Rehabilitation medicine, chongqing general hospital, Chongqing, China
,
Yongmei Li
2   Department of Cardiology, chongqing general hospital, Chongqing, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective Trigeminal nerve stimulation may have some potential in treating migraine, and this meta-analysis aims to study the efficacy and safety of trigeminal nerve stimulation for migraine patients.

Methods We have searched several databases including PubMed, EMbase, Web of science, EBSCO and Cochrane library databases, and selected the randomized controlled trials (RCTs) comparing the efficacy of trigeminal nerve stimulation for migraine patients. This meta-analysis was conducted using the random-effect or fixed-effect model based on the heterogeneity.

Results Four RCTs were included in this meta-analysis. Compared with sham procedure in migraine patients, trigeminal neurostimulation benefited to improve pain freedom at 2 h (OR=2.69; 95% CI=1.30 to 5.56; P=0.007), pain relief at 2 h (OR=2.05; 95% CI=1.53 to 2.74; P<0.00001), pain freedom at 24 h (OR=2.00; 95% CI=1.42 to 2.81; P<0.0001) as well as pain relief at 24 h (OR=1.71; 95% CI=1.25 to 2.33; P=0.0007), and reduce rescue medication (OR=0.70; 95% CI=0.52 to 0.95; P=0.02), but demonstrated no obvious impact on the incidence of adverse events (OR=2.24; 95% CI=1.21 to 4.13; P=0.01).

Conclusions Trigeminal nerve stimulation is effective and safe for the treatment of migraine patients.

Zusammenfassung

Ziel Die Trigeminus-Nervenstimulation kann ein gewisses Potenzial bei der Behandlung von Migräne haben, und diese Meta-Analyse zielt darauf ab, die Wirksamkeit und Sicherheit der Trigeminus-Nervenstimulation bei Migränepatienten zu untersuchen.

Methoden Wir haben mehrere Datenbanken durchsucht, darunter PubMed, EMbase, Web of Science, EBSCO und Cochrane Bibliotheksdatenbanken und die randomisierten kontrollierten Studien (RCTs) ausgewählt, die die Wirksamkeit der trigeminalen Nervenstimulation bei Migränepatienten vergleichen. Diese Metaanalyse wurde anhand des Zufalls- oder Fixed-Effect-Modells basierend auf der Heterogenität durchgeführt.

Ergebnisse Vier RCTs wurden in diese Metaanalyse einbezogen. Im Vergleich zum Scheinverfahren bei Migränepatienten verbesserte die trigeminale Neurostimulation die Schmerzfreiheit bei 2 h (OR=2.69; 95% CI=1.30 bis 5.56; P=0.007), Schmerzlinderung bei 2 h (OR=2.05; 95% CI=1.53 bis 2.74; P<0.00001), Schmerzfreiheit bei 24 h (OR=2.00; 95% CI=1.42 bis 2.81; P<0.0001) sowie Schmerzlinderung bei 24 h (OR=1.71; CI=1.25% bis 5.56; P=0.007), und Rettungsmedikamente reduzieren (OR=0,70; 95% CI=0,52 bis 0,95; P=0,02), zeigten jedoch keinen offensichtlichen Einfluss auf die Inzidenz unerwünschter Ereignisse (OR=2,24; 95% CI=1,21 bis 4,13; P=0,01).

Schlussfolgerungen Trigeminale Nervenstimulation ist wirksam und sicher für die Behandlung von Migränepatienten.

Key words

headache - pain - physical therapies

Schlüsselwörter

Physikalische Medizin - Rehabilitation - Therapie


Publication History

Received: 09 February 2023

Accepted: 21 June 2023

Article published online:
25 July 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Vos T, Allen C, Arora M. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388: 1545-1602
    CrossrefPubMedGoogle Scholar
  • 2 Charles A. The pathophysiology of migraine: implications for clinical management, The Lancet. Neurology 17 2018; 174-182
    PubMedGoogle Scholar
  • 3 Burch R. Migraine and Tension-Type Headache: Diagnosis and Treatment. The Medical clinics of North America 103 2019; 215-233
    CrossrefPubMedGoogle Scholar
  • 4 Ashina M, Terwindt GM, Al-Karagholi MA. et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet (London, England) 397 2021; 1496-1504
    CrossrefPubMedGoogle Scholar
  • 5 Olla D, Sawyer J, Sommer N. et al. Migraine Treatment. Clinics in plastic surgery 47 2020; 295-303
    CrossrefPubMedGoogle Scholar
  • 6 Gökçek E, Kaydu A. The effects of music therapy in patients undergoing septorhinoplasty surgery under general anesthesia. Brazilian journal of otorhinolaryngology 86 2020; 419-426
    CrossrefPubMedGoogle Scholar
  • 7 Sacco S, Amin FM, Ashina M. et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. The journal of headache and pain 2022; 23: 67
    CrossrefPubMedGoogle Scholar
  • 8 Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia: an international journal of headache 2018; 38: 1-211
    CrossrefPubMedGoogle Scholar
  • 9 Reuter U, Ehrlich M, Gendolla A. et al. Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia: an international journal of headache 2022; 42: 108-118
    CrossrefPubMedGoogle Scholar
  • 10 Overeem LH, Peikert A, Hofacker MD. et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study. Cephalalgia: an international journal of headache 2022; 42: 291-301
    CrossrefPubMedGoogle Scholar
  • 11 Lipton RB, Munjal S, Alam A. et al. Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences. Headache 2018; 58: 1408-1426
    CrossrefPubMedGoogle Scholar
  • 12 Lipton RB, Bigal ME, Diamond M. et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343-349
    CrossrefPubMedGoogle Scholar
  • 13 Goadsby PJ, Wietecha LA, Dennehy EB. et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain: a journal of neurology 2019; 142: 1894-1904
    CrossrefPubMedGoogle Scholar
  • 14 Croop R, Goadsby PJ, Stock DA. et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet (London, England) 2019; 394: 737-745
    CrossrefPubMedGoogle Scholar
  • 15 Voss T, Lipton RB, Dodick DW. et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia: an international journal of headache 2016; 36: 887-898
    CrossrefPubMedGoogle Scholar
  • 16 Mayans L, Walling A. Acute Migraine Headache: Treatment Strategies. American family physician 2018; 97: 243-251
    PubMedGoogle Scholar
  • 17 Dodick DW, Martin VT, Smith T. et al. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004; 44: S20-S30
    CrossrefPubMedGoogle Scholar
  • 18 Tepper SJ, Millson D. Safety profile of the triptans. Expert opinion on drug safety 2003; 2: 123-132
    CrossrefPubMedGoogle Scholar
  • 19 Peters GL. Migraine overview and summary of current and emerging treatment options. The American journal of managed care 2019; 25: S23-s34
    PubMedGoogle Scholar
  • 20 Wells RE, Bertisch SM, Buettner C. et al. Complementary and alternative medicine use among adults with migraines/severe headaches. Headache 2011; 51: 1087-1097
    CrossrefPubMedGoogle Scholar
  • 21 Kuruvilla DE, Mehta A, Ravishankar N. et al. A patient perspective of complementary and integrative medicine (CIM) for migraine treatment: a social media survey. BMC complementary medicine and therapies 2021; 21: 58
    CrossrefPubMedGoogle Scholar
  • 22 Vecchio E, Gentile E, Franco G. et al. Effects of external trigeminal nerve stimulation (eTNS) on laser evoked cortical potentials (LEP): A pilot study in migraine patients and controls. Cephalalgia. 2018; 38: 1245-1256
    CrossrefPubMedGoogle Scholar
  • 23 Kuruvilla DE, Mann JI, Tepper SJ. et al. Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM). Scientific reports 2022; 12: 5110
    CrossrefPubMedGoogle Scholar
  • 24 Tepper SJ, Grosberg B, Daniel O. et al. Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized controlled trial. Headache 2022; 62: 989-1001
    CrossrefPubMedGoogle Scholar
  • 25 Daniel O, Tepper SJ, Deutsch L. et al. External Concurrent Occipital and Trigeminal Neurostimulation Relieves Migraine Headache: A Prospective, Randomized, Double-Blind, Sham-Controlled Trial. Pain and therapy 2022; 11: 907-922
    CrossrefPubMedGoogle Scholar
  • 26 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj 2009; 339: b2535
    CrossrefPubMedGoogle Scholar
  • 27 HigginsJPT G. Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. The cochrane collaboration. 2011
    PubMedGoogle Scholar
  • 28 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996; 17: 1-12
    CrossrefPubMedGoogle Scholar
  • 29 Kjaergard LL, Villumsen J, Gluud C. Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses. Annals of Internal Medicine 2001; 135: 982-989
    CrossrefPubMedGoogle Scholar
  • 30 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002; 21: 1539-1558
    CrossrefPubMedGoogle Scholar
  • 31 Chou DE, Shnayderman Yugrakh M, Winegarner D. et al. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia: an international journal of headache 2019; 39: 3-14
    CrossrefPubMedGoogle Scholar
  • 32 Riederer F, Penning S, Schoenen J. Transcutaneous Supraorbital Nerve Stimulation (t-SNS) with the Cefaly(®) Device for Migraine Prevention: A Review of the Available Data. Pain and therapy 2015; 4: 135-147
    CrossrefPubMedGoogle Scholar